search
Back to results

Phage Therapy for the Treatment of Urinary Tract Infection

Primary Purpose

Recurrent Urinary Tract Infection

Status
Active
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Phage Therapy
Sponsored by
Unity Health Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Recurrent Urinary Tract Infection focused on measuring Phage Therapy, Recurrent urinary tract infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of recurrent chronic urinary tract infections with severe long term effects
  • Can speak and understand English
  • Willing to follow the protocol

Exclusion Criteria:

  • Stage 5 chronic kidney disease
  • Abnormal liver function tests
  • A urinary stent or chronic indwelling catheterization
  • A known allergy to phage products
  • Fever
  • Pregnancy
  • Involved in another clinical trial

Sites / Locations

  • St. Joseph's Health Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Open Label Arm

Arm Description

Outcomes

Primary Outcome Measures

Safety and Tolerability
The primary objective is to determine the safety and tolerability of minimally invasive bacteriophage therapy for treating recurrent urinary tract infections with severe long-term effects. These will be assessed through the use of a daily symptom questionnaire, adverse events (AEs), clinical and research laboratory results.

Secondary Outcome Measures

Clinical and microbial response
The secondary objective is to evaluate the 90-day clinical outcomes through a daily paper questionnaire and microbial response assessed through a series of blood, urine, stool, and vaginal sample, to the minimally invasive administration of bacteriophages for recurrent urinary tract infections with severe long-term outcomes.

Full Information

First Posted
September 9, 2022
Last Updated
June 19, 2023
Sponsor
Unity Health Toronto
Collaborators
Applied Health Research Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT05537519
Brief Title
Phage Therapy for the Treatment of Urinary Tract Infection
Official Title
Phage Therapy for the Treatment of Urinary Tract Infection
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 1, 2023 (Actual)
Primary Completion Date
September 15, 2025 (Anticipated)
Study Completion Date
December 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Unity Health Toronto
Collaborators
Applied Health Research Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of bacteriophage therapy to treat and prevent the recurrence of a drug-resistant urinary tract infection with serious long-term effects. This study will follow a minimally invasive phage therapy approach consisting of oral, topical (opening of the urethra) and bladder installations of a 3-phage cocktail comprised of HP3, HP3.1 and ES19.
Detailed Description
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of bacteriophage therapy to treat and prevent the recurrence of a drug-resistant urinary tract infection. This study will follow a minimally invasive phage therapy approach consisting of oral, topical and bladder installations of a 3-phage cocktail comprised of HP3, HP3.1 and ES19. Oral and bladder installation of bacteriophages will be administered on day 1 - and potentially day 7 depending on day 5 urine and stool lab results - and a topical preparation will be applied externally to the urethra for 30-minutes on days 1 to 3. However, if the participant is still experiencing mild symptoms on day 5, systemic antibiotics will be administered in combination with phage therapy. The primary objective is to determine the safety and tolerability of minimally invasive bacteriophage therapy for treating recurrent urinary tract infections with severe long-term effects. The secondary objective is to evaluate the 90-day clinical and microbial response to the minimally invasive administration of bacteriophages for recurrent urinary tract infections with severe long-term outcomes. The total duration of participant involvement is 2 years, while the study is estimated to be completed in 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Urinary Tract Infection
Keywords
Phage Therapy, Recurrent urinary tract infection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Open Label Arm
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
Phage Therapy
Intervention Description
3-phage cocktail comprised of HP3, HP3.1 and ES19
Primary Outcome Measure Information:
Title
Safety and Tolerability
Description
The primary objective is to determine the safety and tolerability of minimally invasive bacteriophage therapy for treating recurrent urinary tract infections with severe long-term effects. These will be assessed through the use of a daily symptom questionnaire, adverse events (AEs), clinical and research laboratory results.
Time Frame
90 Days
Secondary Outcome Measure Information:
Title
Clinical and microbial response
Description
The secondary objective is to evaluate the 90-day clinical outcomes through a daily paper questionnaire and microbial response assessed through a series of blood, urine, stool, and vaginal sample, to the minimally invasive administration of bacteriophages for recurrent urinary tract infections with severe long-term outcomes.
Time Frame
90 Days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of recurrent chronic urinary tract infections with severe long term effects Can speak and understand English Willing to follow the protocol Exclusion Criteria: Stage 5 chronic kidney disease Abnormal liver function tests A urinary stent or chronic indwelling catheterization A known allergy to phage products Fever Pregnancy Involved in another clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gregory German, MD PhD FRCPC
Organizational Affiliation
Unity Health Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Joseph's Health Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M6R 1B5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Phage Therapy for the Treatment of Urinary Tract Infection

We'll reach out to this number within 24 hrs